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1CHAPTER I
RESEARCH PROBLEM
Introduction to Topic
Streptozotocin (STZ) is an antibiotic used to induce diabetes in experimental
animals. STZ produces an immediate and highly specific toxic effect on the insulin-
secreting beta cells of the islets of Langerhans which is followed by a chronic diabetic state
(Rerup 1970). The mechanism by which S12 induces diabetes is controversial and
undefined. The nutritional status of the experimental animal and the metabolic status of the
pancreatic beta cells may influence the animal's response to injected STZ (Preston 1985).
Chromium is an essential trace element for animals and humans (Anderson et al.
1985). The primary known role ofchromium is the potentiation of insulin. Diabetic-like
symptoms, including impaired glucose tolerance and elevated insulin, were observed in rats
fed diets low in chromium (Mertz and Schwarz 1959, Mertz et al. 1965, Schroeder 1965,
Schroeder 1966). In chromium deficiency a higher dose of insulin was required to elicit
the same metabolic response seen in chromium adequacy (Mertz et a11965, Mertz et a1.
1961, Roginski 1969, Schroeder 1966). Striffler et a!. studied the effects of dietary
chromium on insulin secretion in perfused rat pancreata First phase insulin release was
decreased by 40 to 50% in chromium deficient rats as compared to controls (1993). These
data suggest that chromium may playa role in preservation of pancreatic beta cells.
Manganese is essential for all species. Rats fed manganese-free diets exhibited
poor growth, testicular atrophy,. and sterility (Kemmerer et a1. 1931, Orent et a1. 1931).
Defects in carbohydrate metabolism have been reported in manganese-deficient rats and
2mice. Everson and Shrader reported impaired glucose tolerance and pancreatic pathology
in severely manganese-deficient newborn guinea pigs (1'968). Other studies of manganese-
deficient animals have reported aplasia and/or hypoplasia of pancreatic cells (Zidenberg-
Cherr 1990). Decreased pancreatic insulin synthesis, enhanced intracellular insulin
degradation, and decreased insulin secretion have been observed in manganese-deficient
animals '(Baly et ,aI. 1985). Manganese deficiency is also associated with abnonnallipid
metabolism and alterations in cellular integrity. Zidenberg-Cherr et al.(l983) reported
decreased manganese dependent supero:xide dismutase (MnSOD) activity and increased
lipid peroxidation in manganese-deficient mts. Tissue MnSOD levels were influenced by
dietary manganese intake (Davis et al. 1990).
Significance of the Problem
It has been posmlated that STZ acts as an oxidant resulting in changes in the redox
state of the islet cell. Oxidative stress produces an acute rise in oxidized glutathione and a
fall in reduced glutathione (Slonim et at 1976. Slonim et al. 1983). Slonim et aI. found
that S12 administered in vivo to rats produced a rapid fall in red blood cell reduced
glutathione. Copper-zinc superoxide dismutase (Cu-ZnSOD) is present in the islets of
Langerhans ofrats. Crouch et a1. (1981) found that STZ inhibited islet Cu-ZnSOD activity
in vitro and had no effect on MnSOD. Gandy et a1.(1982) investigated the potential of
exogenous polyethylene glycol-derivatized superoxide dismutase (PEG-SOD) to prevent
STZ-induced diabetes in rats. They found that PEG-SOD injected 10 seconds or 50
minutes prior to administration of STZ prevented or significantly attenuated diabetes. In a
study by Slonirn et aI. (1983) the administration of the anti-oxidant vitamin E prior to STZ
injections in rats provided protection against the diabetogenic drug. Rats maintained on a
vitamin E and selenium-deficient diet demonstrated enhanced diabetogenic response to
nonnally nondiabetogenic doses of S12. These data support the postulate that STZ acts as
an oxidant or a free radical producer. However, the role of STZ as an oxidative stressor or
3free radical generator remains controversial since other studies of the administtation of
exogenous SOD and Vitamin C did not fmd'any protective effects of these anti-oxidants
against the cytotoxic effects of STZ (Gold et al. 1981, Yew 1983).
As the westernized diet has become more highly processed there has been an
increase in the loss of chromium (Schroeder 1968, Anderson 1987, Kozlovsky et aL
1986). The world wide trend towards a highly processed and refined diet, which is not
only low in chromium but may also stimulate chromium losses, may result in marginal
chromium status. Mean chromium intake in the United States and most developed
countries is approximately 50 to 60% of the lower end of the estimated safe and adequate
range (Anderson and Kozlovsky 1985). In addition the Food and Drug Administration's
Total Diet Study (1982-86) found manganese intakes for teenage, adult, and elderly women
to be slightly less than the estimated safe and adequate daily dietary intake (Pennington et
al. 1989).
Chromium and manganese appear to have roles in the protection of the beta cells of
the pancreas. If chromium and/or manganese intakes are suboptimal the beta cells may be
increasingly susoeptible to oxidative stressors and/or to the effects of diabetogenic agents
such as STZ.
Objectives
The objectives of this research are to investigate the effects of two trace minerals
(chromium and manganese) on glucose metabolism (as measured by glucose tolerance,
insulin, and weight loss) and kidney and liver mineral concentrations in streptowtocin-
injected rats.
The following hypotheses were developed for this study:
1. There will be no statistically significant independent and or interactive
effect(s) of dietary chromium and/or manganese on change in body weight,
4tissue weights as percent body weight. glucose tolerance. or serum insulin,
frusctosamine, or corticos~eroneconcentrations in streptozotocin-injected
rats.
2. There will be no statistically significant independent and/or interactive
effect(s) of dietary chromium and or manganese on liver and kidney mineral
concentrations in streptozotocin-injeeted rats.
Limitations
This study evaluated the effects of a relatively short tenn chromium and manganese
deficiency. Thus the effect of chronic mineral deficiencies were not evaluated. The study
evaluated the effects of deprivation or adequate intakes of the two trace minerals, thus the
effects of supplementation were not studied. Trace mineral deficiencies are difficult to
establish; chromium is particularly problematic due to increased risk of environmental
contamination. A further limitation is the intraperitoneal administration of streptozotocin
which is inherently more variable than injecting streptozotoein intravenously.
Fonnat of Thesis
Chapter In is written in manuscript fonn using the guide for authors for the Journal
of Nutrition.
5CHAPTER II
REVIEW OF 1HE LITERATURE
This chapter reviews the literature on chromium and manganese and their roles in
glucose metabolism. The use of streptozotocin as a diabetogenic agent in laboratory
animals also is reviewed.
Chromium
Chromium is an essential trace element in animals and humans (Anderson et al.
1985). It is a transition element occurring in eight oxidation states, the most common states
being 0,2+,3+, and 6+. The triva],ent state is the most stable (Anderson 1990). A
biologically active fonn of chromium was isolated from brewers' yeast and pork kidney
powder by Schwarz and Mertz in the late 1950s and tenned glucose tolerance factor
(1959). The exact structure of glucose tolerance factor (GTF) remains undefined and
controversial, however it is believed to contain two nicontinic acid molecules per trivalent
chromium atom and either amino acids or glutathione (Flatt et al. 1989, Mertz 1992).
Some organic chromium complexes have considerably greater biological activity than
chromium salts (Mertz, 1976).
In a review of 15 controlled studies of the effects of supplementation with defmed
Cr3+ compounds in subjects with impaired glucose tolerance, three studies found no
effects of supplementation while twelve studies found improved glucose tolerance and
efficiency of the insulin (Mertz, 1993). Ranhotra and Gelroth studied the effects of
chromium supplementation, in forms of either high chromium bakers' yeast or chromium
chloride, on response to a glucose load in rats fed a chromium-deficient diet for 17 weeks.
6R.ats supplemented with bakers' yeast had a smaller rise in blood glucose compared to
fuose supplemented with chromium chloride (1986).
Distribution
Chromium is widely distributed in the body with no known specific concentration
in any tissue or organ (Anderson 1987). There have been few definitive studies on
chromium concentration in tissues of animals and humans as there are numerous problems
with chromium contamination in sampling and analysis. Current sampling and analysis
methods can reduce the risks of contamination but the number of studies using these
methods is limited. Thus, caution shouMd be used in viewing historic data on clrromium
,content of tissues (Anderson 1987). Chromium concentration in tissues may be several
times higher than that in the blood and thus is not in equilibrium (Anderson 1994). In
general, tissue chromium concentrations tend to be lower in parts of the world where there
is a higher incidence of non-insulin dependent diabetes mellitus and atherosclerosis
(Anderson 1987). There is no reliable method to assess chromium status other than
response to chromium supplementation (Anderson et a1. 1985).
Absorption
Trivalent chromium and inorganic chromium compounds are poorly absorbed by
animals and man (Donaldson and Barreras 1966, Mertz et a1. 1974). Reported absorption
of chromium compounds ranges from 0.5 to 3% (Anderson 1987, Stoecker 1990).
Chromium absorption is rapid with the greatest absorption occurring in the midsection of
the small intestine (Chen et al. 1973). Urinary chromium excretion is considered a fairly
accurate estimate of absorption (Anderson 1985) and a poor indicator of chromium status
(Anderson 1983). Anderson and Kozlovsky smdied chromium intake and absorption in
subjects consuming self-selected diets. They detennined that absorption is inversely related
to intake. When chromium intakes were approximately 10 ug per day, absorption was
7approximately 2%. When intakes increased to approximately 40 ug perday, abserpti.en:
decreased to about 0.5% (1985). There is no apparent difference in absorption of CrC13
supplements and chromium from dietary sources (Anderson et a1. 1985).
Mineral interactions and chelation affect chromium absorption. While oxalate
increases absorption of chromium, phytate appears to decrease absorption by ,a lesser
degree (Chen et aI. 1973). Chromium absorption is enhanced in zinc deficiency, and
absorption is decreased by zinc supplementation. Furthennore. zinc absorption is greater
in chromium deficiency and zinc absorption is decreased with chromium supplementation
(Hahn ,et al. 1975). This interaction suggests that zinc and chromium may be metabolized
by a common pathway in the intestine. Chromium and iron appear to compete for
absorption since iron-deficient animals absorb more chromium than iron-supplemented
animals. Chromium is believed to be transported primarily by transferrin but also by
albumin (Hopkins and Schwarz 1964).
In studies of the effect of carbohydrate source on absorption and tissue chromium
in animals, starch appeared to increase absorption as compared to diets with carbohydrate
sources of sucrose, glucose, and fructose (Seaborn and Stoecker 1989). Diets high in
simple sugars appear to increase urinary excretion of chromium (Kozlovsky et al. 1986).
Separate studies have reported increased urinary excretion of chromium following glucose
loads regardless of chromium status (Anderson et al. 1982, Glinsmann et aI. 1966,. Morris
et al. 1988).
Dletaty Intakes
Reported dietary intakes of chromium range from 24.5 ug/d in England to 56 ug/d
in Canada. Most of the earlier studies may have been plagued with errors in sampling and
analysis involving contamination which may have resulted in erroneously high values
(Anderson 1987). More recent intake data for the United States estimate average intakes to
be approximately 15 ug per 1000 kilocalories (Anderson et al. 1985). In Anderson and
8Kozlovsky'schromium intake study of subjects consuming self-selected diets. 90% ofthe
cHets analy~ed contained less chromium than the estimated safe and adequate daily dietary
intake range (ESADDI) (1985). The safe and adequate range has been established at 50-
200 ug chromium/day (National Research Council 1989). However, at intakes of 50 ug/d,
the lower end of the recommended amounts, signs and symptoms of chromium deficiency
did not develop (RDA, 1989). Long tenn effects of intakes less than 50 ug/d have not been
fully investigated. Mean chromium intake in the United States and most developed
countries is approximately 60% of the lower end of the estimated safe and adequate range
for males and about 50% for females (Anderson and Kozlovsky 1985). Freely chosen
diets and diets designed by nutritionists contained about the same ratio of chromium to
kilocalories, 15 ug chromium per 1000 kilocalories (Anderson et al. 1992).
Significant amounts of chromium are lost in milling and refining of certains foods
(Schroeder 1968). White flour contains 35-55% of the chromium found in whole wheat
products and unrefined sugar contains 40% less chromium than molasses. Brown and
white sugar contain 24% and 8% of the chromium in the unrefined sugar (Anderson 1987).
A diet high in refined sugar not only lends itself to a diet low in chromium but may also
contribute to increased urinary losses of chromium (Kozlovsky et at. 1986). In general,
the less refmed and processed a diet, the higher the content of chromium. The world wide
trend towards a highly processed and refined diet which is not only low in chromium but
may stimulate chromium losses may result in marginal chromium status (Anderson and
Kozlovsky 1985). Meats and whole-grain products appear to be the best sources while
fruits, vegetables, and milk are quite low in chromium (RDA, 1989). There may be
significant amounts of chromium added to the food supply during preparation and
processing particularly with the use of stainless steel in an acid environment during which
chromium is leached out of the stainless steel (Offenbacher and Pi-Sunyer 1983).
Chromium and Glucose Homeostasis
The roles of chromium in nutrition have been studied for several decades. The
primary role is the potentiation of insulin. Evans~ Roginski, and Mertz studied the
interaction ofGTF, extracted from brewers' yeast, and insulin and their ,effects on glucose
metabolism in epididymal fat tissue. They found that GTF bound to insulin and produced
greater glucose uptake into epididymal tissue than did insulin alone (1973). Diabetic-like
symptoms, including impaired glucose tolerance and elevated insulin, were observed in rats
maintained in a typical laboratory environment and fed rations and diets low in chromium.
A decreased rate ofglucose removal was observed although there was no difference in
growth rates compared to rats fed standard rations. Low glucose removal rates were
reversed with the addition of chromium to the diet in the form of brewers' yeast or pork
kidney powder (Menz and Schwarz 1959). Overt deficiency may not have been
established in this study secondary to environmental chromium contaminants. When
experimental animals were raised in a strictly controlled environment designed to decrease
sources of chromium contamination and fed a low chromium diet, more severe symptoms
of deficiency were apparent such as depressed growth and survival in addition to glucose
intolerance, fasting hyperglycemia, and glycosuria (Mertz et al. 1965). Dietary chromium
supplementation of 5 ppm helped to reverse these trends. Young rats fed a low chromium
torula yeast diet exhibited decreased growth rates, increased early mortality, and glucosuria
(Schroeder 1965, Schroeder 1966). These data support the essentiality of chromium in
animals.
More recently chromium supplementation in patients on long tenn total parenteral
nutrition (TPN) eliminated the need for exogenous insulin and helped to nonnalize blood
glucose values (Brown et al. 1986, Freund et at 1979, Jeejeebhoy et al. 1977). One
patient had been on TPN for 3 years and developed severe diabetic-like symptoms
including weight loss, glucose intolerance, and peripheral neuropathy (Jeejeebhoy et al.
1977). Chromium supplementation to TPN solutions corrected the metabolic aberrations.
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A similar syndrome was seen in a patient who had been on TPN for 5 months (Freund et
al. 1979). Chromium by itself is not a hypoglycemic agent. Insulin must be present for
biological activity to occur. Furthermore, chromium supplementation is benefiCial only if a
deficiency is present (Mertz et aI. 1965, Glinsmann and Mertz 1966).
The primary biochemical lesion of chromium deficiency is proposed to be the
decreased insulin sensitivity of peripheral.tissues (Mertz et aI. 1965). Chromium has been
hypothesized to be essential in the assembly of insulin and its receptor sites in cell
membranes (Govindaraju et al. 1989). In chromium deficiency a greater dose of insulin is
required to elicit the same metabolic response seen in chromium adequacy (Mertz et al.
1965, Mertz et al. 1961, Roginski 1969, Schroeder 1966). In a study of the effects of
dietary chromium on insulin secretion in perfused rat pancreata, first phase insulin release
was decreased by 40 to 50% in chromium deficient rats as compared to their controls.
These data suggest that chromium may playa role in preservation of the beta cells of the
pancreas (Striffler et al. 1993).
In studies evaluating the benefits of chromium supplementation in hypoglycemic
subjects, there were significant improvements in hypoglycemic glucose values and
symptoms following supplementation (Clausen 1988). Anderson et aI. studied the effects
of chromium (200 ug/d) supplementation on response to a glucose challenge in 76 free-
living human subjects. Subjects with pre-supplementation fasting glucose values greater
than or equal to 100 mg/dl had decreased 90 minute post challenge glucose values after
supplementation. Subjects with pre-supplementation 90 minute post-challenge glucose
values less than fasting levels had a 90 minute blood glucose greater than fasting levels
after supplementation. There was no effect of chromium supplementation in subjects with
90 minute glucoses nearly equal. to fasting values (1983). Thus, it appears that chromium
supplementation may be beneficial not only in regulating blood glucose in the
hyperglycemic state but in the hypoglycemic state as welL
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Not all studies have shown a beneficial response to 'chromium supplementation. It
must be remembered that supplementation is helpful only in a deficient state and that not all
cases of glucose intolerance are secondary to a chromium defidency (Mertz 1976).
Manganese
Manganese is a transition element occurring in 11 oxidation states from -3 to +7
with the most common states being +2, +4. and +7. Divalent manganese is the dominant
fonn in biological structures. Mn3+ is the oxidative state in manganese superoxide
dismutase (MnSOD) and is the fonn which binds to transferrin. It is probably the oxidative
state which interacts with Fe3+ (Keen and Zidenberg-Cherr 1994).
Manganese is essential is all species. Essentiality of manganese was first reported
in 1931. Kemmerer et al. reported poor growth in mice fed a manganese- free diet (1931).
Male rats raised. on manganese-free diets developed testicular atrophy and sterility (Orent et
aL 1931). Essentiality for humans was established in 1972 by Doisy (1972). A male
subject fed a purified diet in a vitamin K deficiency study inadvenently developed
manganese deficiency when the mineral was accidently omitted. from the diet. The
symptoms. which were not consistent with those associated with vitamin K deficiency,
included weight loss and hypocholesterolemia (Doisy 1972).
Distribution
Manganese is widely distributed in tissues and fluids without any notable
concentration in anyone location. There is little variation among species, organs. or age
(Keen and Zidenberg-Cherr 1990). There is a greater concentration of manganese in
mitochondria than in cytoplasm or other cellular components (Keen and Zidenberg-Cherr
1990). Muscle has the lowest concentration of manganese while bones contain about 25%
of the total body content. There is a lack of practical methods to assess manganese status.
In a study by Keen et aI. blood manganese levels appeared to reflect body manganese
l2
concentration in rats fed either manganese-deficient or manganese-adequate diets (1983).
This finding has not been useful in humans as the results of human studies have not
reproducible (RDA. 1989). " ,
Absorption
Manganese absorption is variable,. ranging from 2 'to 15% of intake in studies using
54Mn labeled test meals (Keen and Zidenberg-Cherr 1990). Freeland-Graves et a1. (1988)
reponed grea~er than 17% of dietary manganese absorbed in a metabolic balance study of
young men. Sources of variation might be due to variability in absorption among subjects,
individual body stores of manganese. and composition of the diet. Davis et a1. (1992)
detennined that the efficiency of manganese absorption increased when rats were fed
manganese-deficient (0.9 ug/g) diets. The percent absorbed tended to be greater when fed
diets with adequate manganese (48 ug/g) than when fed diets high (188 ug/g) in dietary
manganese.. Manganese is absorbed quickly and equally throughout the small intestine and
is excreted in the feces (Thompson et al1978). Data from Garcia-Amanda et al. (1983)
suggests that intestinal manganese absorption is a rapidly saturable process and decreases
linearly with time. Absorption of manganese has not commonly been thought to be under
homeostatic control (Thompson 1971). However, Davis et at (1992) investigated the
effects of varying levels of iron and manganese on gut absorption and endogenous losses
of manganese by rats and concluded that control of gut absorption did appear to be the
major mechanism of homeostatic control.
Manganese and iron are thought to compete for absorption in animals and humans.
Iron supplementation inhibits manganese absorption and vice versa (Davis et al. 1990,
Davis et al. 1992, Groden 1988. Thomson et al. 1971). Davis et al. (1992) suggested that
iron depressed manganese absorption by inhibiting manganese uptake into the mucosal
cells. Although the actual mechanism is undefmed, it may involve a common
. transportation site as both manganeses and iron are carried by transfenin (Davidsson
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1989). Thiets high in dietary fiber, calcium, phytate, and pbosphorous increase the need for
manganese due to probable fonnation of insoluble complexes in the gut which decrease the
total manganese availabl'e for uptake (Davidsson 1988, Davies et aI. 1975). The
I
significance of this in humans is undetennined.
Nearly all manganese is excreted througb the intestinal wall by several
interdependent routes which makes for an efficient homeostatic control of tissue levels
(Britton et a1. 1966,. Davidsson et a1. 1991). Under nonnal conditions bile is the primary
excretory route. There is also some excretion through pancreatic juices and sloughed
intestinal cens (Davis et aI. 1992). Very littIe manganese is lost through urine (Keen and
Zidenberg-Cherr 1990). Many studies have detennined that variable manganes'e excretion
is the major point of homeostatic control (Britton et a1. 1966, Davidsson et al. 1991).
However, the recent study by Davis et a1. (1992) proposing that true absorption is the
major mechanism of homeostatic control of tissue mangan'ese levels warrants careful
consideration and further research in this area.
The 1989 Recommended Dietary Allowances (National Research Council 1989)
included a estimated sa.£e and adequate daily dietary intake (ESADDI) of manganese for
adults of 2.0 to 5.0 mg per day. The Food and Drug Administration's Total Diet Study
(1982-86) found manganese intakes for young children, teenage boys, adult and el,derly
males to be within the ESADDI ranges. Infants' intakes were found to be greater than the
ESADDI and teenage girls and adult and ,elderly females' intakes were slightly less than the
recommended ranges (Pennington et a1. 1989). Good sources of manganese include tea,
whole grains, nuts, dried fruits, and leafy vegetables. Poorer sources are dairy products,
meats, fish, and poultry (RDA, ]989).
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Manganese Deficiency
Manganese deficiency has been demonstrated in most species (Keen and Zidenberg-
Cherr 1994). In experimental animals manganese deficiency affects endocrine and exocrine
functions (Chang et al. 1990) .. Symptoms of deficiency include impaired growth and
skeletal abnonnalities secondary to reductions in proteoglycan synthesis resulting from
decreased manganese glycosyl-transferase activity (Baly et al. 1985). The reduction in this
manganese dependent enzyme also adversely affects the development of otoliths in the
offspring of manganese-deficient animals. Impaired otolith foonation results in severe and
irreversible ataxia characterized by a lack of coordination and equilibrium and head
retraction (Keen and Zidenberg-Cherr 1990). Manganese deficiency also has been reponed
to alter reproductive perfonnance (Orent et al. 1931).
Defects in carbohydrate metabolism have been reported in manganese deficient rats
and mice. In a study of newborn guinea pigs with severe manganese deficiency, Everson
and Shrader reported pancreatic pathology and impaired gLucose tolerance. The
manganese-deficient guinea pigs displayed elevated fasting blood glucose and responded to
a glucose challenge with a diabetic-like glucose tolerance curve. Manganese
supplementation for two months normalized the guinea pigs' response to glucose
administration (1968). Other studies of manganese-deficient animals have reported aplasia
and/or hypoplasia of pancreatic cells with a smaller number of islet cells, and fewer and
less granulated beta cells (Zidenberg-Cherr 1990).
In a study of the effects of manganese deficiency on insulin-binding and glucose
transport and metabolism in rat adipocytes, it was found that second generation manganese
deficient rats fed a diet low (l ug Mn/g diet) in manganese had fewer insulin receptors per
cell, a decreased glucose transport velocity in adipocytes, and decreased insulin stimulated
glucose oxidation. These data suggest manganese deficiency decreases the number of
glucose transporters in the adipose tissue of manganese-deficient rats (Baly et al. 1990).
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Minor changes in gluconeogenesis and glycogenolysis have been observed in
deficient animals.. The most r'emarkable changes are decreased pancreatic insulin synthesis,
enhanced intracellular insulin degradaton, and decreased insulin secretion (BaIy et aI.
1985). In a study of second generation manganese deficient rats, Baly et al (1984)
evaluated insulin stores and release from isolated peifused pancreata Decreased stored
insulin or impaired release of the hormone in the deficient rats as compared to controls
contributed to the diabetic-like response to a glucose load. The effects of manganese
deficiency on insulin are essentially unknown although insulin mRNA levels are reduced in
manganese-deficient animals (Keen and Zidenberg-Cherr 1990). Werner et al.(l987)
reported decreased hepatic and pancreatic manganese content in manganese-deficient rats.
The decrease was more pronounced in the liver than in the pancreas which may suggest a
homeostatic mechanism to conserve manganese in tissues where it is needed most.
Manganese deficiency is also associated with abnonnallipid metabolism with
alterations in cellular integrity secondary to increased membrane lipid peroxidation. This
lipid peroxidation may be related to the observed decrease in manganese dependent
superoxide dismutase (MnSOD) activity in manganese-deficient animals ('Thompson et aI.
1992, Zidenberg-Cherr et at 1983). Zidenberg-Cherr et aI. investigated MnSOD activity
and lipid peroxidation in the manganese-deficient rat Decreased MnSOD activity resulted
in increas'ed lipid peroxidation by free radicals, and might have contributed to the observed
damage to mitochondrial membranes. Thompson et aI. (1992) studied the effects of
manganese deficiency on tissue anti-oxidant status in streptozotocin (STZ) induced diabetic
rats. Decreased kidney and heart MnSOD activity was observed in the STZ-injected rats
and in their controls. The decreased kidney MnSOD was more pronounced in the STZ-
injected rats than in the controls. These STZ-injected rats also had an increase in liver
MnSOD and increased lipid peroxidation. These data demonstrate an interaction between
manganese deficiency and STZ-induced diabetes resulting in an amplification of tissue and
16
antioxidant changes seen with either condition alone. They also support an antioxidant role
for manganese.
Man~anese and Glucose Metabolism
Manganese functions as a component of metalloenzyrnes and as an enzyme
activator. Manganese metalloenzymes include arginase, pyruva'te carboxylase, and
manganese superoxide dismutase (MnSOD) (Baly et al. 1983, Keen and Zidenberg-Cherr
1994). Arginase is essential in the fonnation of urea. In rnanganese-deficient rats, the
arginase concentration is 50% less than that of controls, but the functional significance is
unclear. In experimental diabetes liver and kidney manganese concentrations can be
elevated in addition to an increase in arginase activity. Whether or not diabetes results in an
increased need for manganese in has not been detennined (Keen and Zidenberg-Cherr
1990).
Pyruvate carboxylase catalyzes the conversion of pyruvate to oxalacetate, a key step
in gluconeogenesis. There is a slight decrease in activity of this enzyme in manganese-
deficient animals (Baly et aI. 1985). However there gluconeogenesis is not inhibited in
manganese-deficient animals, presumably because magnesium readily replaces manganese
in this step of gluconeogenisis (Fahim et a1. 1990).
Superoxide dismutase (SOD) is a scavenger of superoxide radicals and protects the
integrity of cell membranes (Gandy et aI. 1983). STZ catalyzes the disproportionation of
02- to H202 + 02 (Davis and Greger 1992, Thompson et a1. 1992). All SODs are
metalloenzymes (Cu, Zn, Mo, or a combination thereof). Tissue MnSOD levels are
influenced by dietary manganese intake (Davis et aI. 1990). Davis and Greger studied
longitudinal changes in MnSOD activity in response to iron and manganese
supplementation in women. Manganese supplementation tended to increase lymphocyte
MnSOD activity (1992). Manganes,e-deficient animals have decreased MnSOD activity in
tissues including liver, brain. heart, pancreas, and kidney (Davis et a1 1990, Keen and
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Zidenberg-Cherr 1990, Thompson et al. 1992). This reduction. is functionally significant
in that increased levels of tissue lipid peroxidation have been observed in manganese-
deficient rats compared to controls (Thompson et aI. 1992). Zindenberg-Chen- et al.
studied the activities of MnSOD, copper-zinc SOD (CuZnSOD), and lipid peroxidation in
the livers of manganese sufficient and deficient rats from birth to 60 days of age.. In both
groups MnSOD activity increased with age, however the activity in the manganese-deficient
group was approximately half that of the sufficient group. There was also a nearly two-fold
greater increase in lipid peroxidation in the manganese-deficient rats as compared to
peroxidation in controls by day 60 (1983). This may explain the increased membmne
,damage in manganese deficient animals.
Th,ere are numerous manganese-activated enzymes including hydrolases, mases,
decarboxylases, and transferases. Many are not manganese specific. For example in a
manganese-deficient state, pyruvate carboxylase can be catalyzed by magnesium (Fahim et
311. 1990). A decrease in phosphoenolpyruvate (PEPCK) activity has been reported in
manganese-deficient animals. PEPCK, like pyruvate carboxylase, is a gluconeogenic
enzyme but is manganese specific (Baly et al. 1985). Manganese specifically activates
glycosyltransferase (Baly et al. (985). Skeletal and otolithic pathologies induced by
manganese defidency have been demonstrated and are related to decreased.
glycosyltransferase activity (Baly et 311. 1985).
Stre,ptowtocin as a DiabetQ~enic Agent
Streptozotocin (STZ) is a diabetogenic agent used to induce experimental diabetes in
laboratory animals (Dulin et 3111983, Mordes and Rossini 1981, Rerup 1970). STZ is a
broad spectrum antibiotic produced by Streptomyces achromogenes and has 4 major
biological properties: antibacterial, antifungal, oncogenic, and diabetogenic (Preston 1985,
Rerup 1970). STZ injected into animals produces an immediate and highly specific toxic
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effect on the beta cells of the islets of Langerhans which is foUowed by a chronic diabetic
state (Remp 1970).
Chemically, STZ consists of a I-methyl-l-nitrosourea linked to position C2 of a D-
glucose (Remp 1970). The nitrosourea moiety is, thought to elicit the cytotoxic effect while
the deoxyg1ucose moiety facilitates entry into the beta cell (Dulin et a1. 1983). The alpha
anomer of STZ demonstrates higher potency than the beta anomer which suggests
involvement of beta cell membrane glucoreceptors which have a greater affmity for the
alpha anomer of D-glucose (Dulin et aI. 1983, Mordes and Rossini 1981). Removal of the
glucose moiety makes STZ much less specific -to beta ceHs (Mordesand Rossini 1981,
Preston 1985).
Once in the beta cell STZ is thought to decrease levels of cellular nicotinamide
adenine dinucleotide (NAD) and impair synthesis of NAD from nicotinamide (Mordes and
Rossini 1981, Dulin 1983, Rerup 1970). In studies by Maldonato et aI., 51'2 inhibited
proinsulin synthesis and insulin release in rat islets in a time and concentration dependent
manner (1976). The role of STZ asa free radical generator is controversial since studies
using vitamin C and exogenous superoxide dismutase (SOD) did not act as significant
protective agents (Gold et a1. 1981, Yew 1983). The potential to develop STZ-induced
diabetes may be influenced by the nutritional status of the experimental animal and by the
metabolic status of the pancreatic beta cells (Preston t 985). Vitamin E and nicotinamide
inhibit the diabetogenic effects of STZ as they prevent the depletion of islet cell NAD
(Mordes and Rossini 1981, Rerup 1970, Slonim et al. 1983).
STZ and other beta cyto~oxins have been reported to inhibit SOD activity in the
retina, islets, and erythrocytes (DaIin et 311. 1983, Gandy et aI. 1983). Gandy et aI.
evaluated the attenuation of STZ diabetes with copper (II)
(3,5-Diisopropyl-salicylate)2 which has SOD-like bioactivity (1983). Administration of
these compounds before STZ injection appeared to attenuate the severity of the induced
diabetes as measured by glucose tolerance and glycosuria. This attenuation may represent a
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partial protection of the beta cells with the <copper containing SOD-like complex (Gandy et
a1. 1983)
STZ-induced diabetes is a widely accepted experimental model (Wright and Lacy
1988). Models for non-insulin dependent diabetes mellitus (NIDDM) have been
established using neonatal mts injected with the antibiotic between days 0 and 2 after birth
(Levy et al. 1984, Portha et al. 1982, 1989. Weir et aI. 1981). In neonatal rats injected
with STZ on day 2 there was initially a transient period of hyperglycemia lasting 2 to 4
days. Then plasma glucose concentrations remained normal for approximately 6 weeks
after which frank hyperglycemia develops with a basal plasma glucose concentration
ranging from 200 to 350 mg/dl and decreased basal plasma insulin values (Levy et al.
1984, Portha et a1. 1982, 1989, Weir et al. 1981). There were no signifi.cant changes in
weight This model appears appropriate for long-tenn studies as the low insulin response
is steady and chronic (Portha et a1. 1982).
Experimental diabetes was induced in adult male and female rats by injecting S12
(55-60 mglkg/i.p.) (Miller et a1. 1988). The diabetic rats presented symptoms of frank:
diabetes including polyuria, glycosuria, and ketonuria within 24-48 hours. Blood glucose
values measured between 300-800 mg/dl (Miller et al. 1988). A milder fonn of diabetes
was induced in adult rats with a smaner dose of STZ (45mg/kg/i.v.). The diabetic rats
exhibited elevated basal non-fasting plasma glucose of about 300 mg/dl without frank
ketosis or insulin dependence (Tancrede et al. 1982).
There is a relationship between the dose of S12 injected and the severity of diabetes
induced in the rat (Tancrede et aI. 1983). Tancrede et aJ. studied the effects of varying
doses (0, 25,35,45,55,65, and 100 mglkg/i.v.) of STZ on glucose tolerance in male
Wistar rats. Intravenous glucose tolerance tests were perfonned at one, four, and sixteen
weeks afrer the STZ injection. Tancrede et al. noted that fasting glucose values were
significantly different from controls 1 week after injection ofdoses greater than or equal to
55 mglkg. Elevation of fasting glucose in rats receiving less than or equal to 45 mg/kg
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became significantly different than controls only at 16 weeks after STZ injection.
Decreases in plasma insulin levels became significantly different from controls only at
doses of 65 mg/kg and 100 mglkg (fancrede et al. 1983).
While caution must be used in extrapolating data derived from experimental diabetes
in animals to diabetes in humans, the usefulness and promise of these animal models to
illustrate the various etiological and pathogenic mechanisms inherent in diabetes is ,critical to
further study of the relationship of nutrition and nutrients to this disease. Diabetes research
in human subjects is complicated by obvious ethical problems. Inducing diabetes in
humans is not pennissible; thus, new treatments and medications must be tested in animals.
Experimental diabetes in animals also provides the opportunity to study the effects of
chronic disease and long tenn usage of therapeutics.
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CHAPTER III
EFFECfS OF DIETARY CHROMIUM AND MANGANESE IN
STREPTOWTOCIN-INJECTED RATS
Jarrett, C.R., Adeleye, B.A., Stoecker,
B.l., and Davis-Whitenack, M.L.
Department of Nutritional Sciences, Oklahoma State
University, Stillwater, OK 74078
ABSTRACT
Using a two by two factorial design, thirty-seven male weanling rats (Sprague-
Dawley) were randomly assigned to one of four casein-based diets low in chromium and
manganese (-Cr -Mn) or supplemented with 1 ppm chromium as chromium chloride (+Cr)
and 3 (-Mn) or 55 ppm (+Mn) manganese as manganese carbonate. Experimental diets and
deionized water were available ad libitum. After seven weeks on the experimental diets, the
rats were injec~ed with streptozotocin (STZ) (45 mglkg body weight, in citrate buffer, pH
4) on two consecutive days. One week after 51'2 injections, a glucose tolerance test was
performed using a 1 glkg body weight glucose load, and blood was collected at 0, 60, 120,
and 180 minutes. Four weeks after STZ injection, rats were fasted for 12 hours and given
a 1 g/kg body weight glucose load two hours before being anesthetized and exsanguinated.
Blood samples were collected from the tail prior to the glucose load and by cardiac puncture
at necropsy. No significant differences were observed in glucose tolerance tests,
fructosamine, plasma insulin, or autopsy glucose concentrations. Manganese and
chromium did have a significant interactive effect on corticosterone concentrations at
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autopsy (p<O.05). Rats fed (+Cr +Mn) diets has significantly lower autopsy corticosterone
concentrations than did rats fed all other diets.
INDEXING KEY WORDS; Rats, chromium, manganese, streptozotocin, glucose
metabolism
Streptozotocin (STZ) is a antibiotic used to induce diabetes in experimental animals.
STZ produces an immediate and highly specific toxic effect on the insulin secreting beta
cells of the islets of Langerhans which is followed by a chronic diabetic state (Rerup 1970).
The nutritional status of the experimental anim.al and the metabolic status of the pancreatic
beta cells may influence the animal's response to injected S'fZ (Preston 1985). The
mechanism by which STZ induces diabetes is controversial and undefined.
S12 may act as an oxidant resulting in changes in the redox state of the islet cell.
Copper-zinc superoxide dismutase (Cu-ZnSOD) is present in the islets ofLangerhans of
rats. STZ inhibited islet SOD activity in vitro yet had no effect on manganese-dependent
SOD (MnSOD). Exogenous polyethylene glycol derivatized superoxide dismutase (pEG-
SOD) injected 10 seconds or 50 minutes prior to STZ injections in rats prevented or
significantly attenuated the resulting diabetes (Crouch et al. 1981). Slonim et aI. (1983)
found that vitamin E injected prior to STZ provided protection against the diabetogenic drug
and that animals maintained on a vitamin E and selenium-deficient diet showed enhanced
diabetogenic response to nonnaUy nondiabetogenic doses of STZ. Gold et a1. (19B1)
studied the effects of exogenous SOD, and Yew (1983) studied the protective effects of
vitamin C on the response to STZ. Neither found protective effects of these anti-oxidants.
Chmmium and manganese are essential for nonnal glucose metabolism. Diabetic-
like symptoms were observed in rats fed diets low in chromium (Mertz and Schwarz 1959,
Mertz et al. 1965, Schroeder 1965,. Schroeder 1966). Chromium's primary role is the
potentiation of insulin. In chromium deficiency a higher dose of insulin is required to elicit
the same metabolic response seen in chromium adequacy (Mertz et aI. 1965, Mertz et al.
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1961, Roginski 1969, Schroeder 1966). First phase insulin secretion ofperfused rat
pancreata is decreased by 40 to 50% in chromium deficient rats as compared to controls
(Sniffler et a1. 1993). Chromium may playa role in the preservation of pancreatic beta
Defects in carbohydrate metabolism have been reported in manganese-deficient rats
and mice. Everson and Shrader reported impaired glucose tolerance and pancreatic
pathology in severely manganese-deficient newborn guinea pigs (1968). Decreased
pancreatic insulin synthesis and secretion and enhanced intracellular insulin degradation
have been observed in manganese deficient animals (Baly et al. 1985). Zidenberg-Cherr et
al reported decreased Mn-SOD activity and increased lipid peroxidation in manganese-
deficient rats (1983). Tissue MnSOn levels were influenced by dietary manganese intake
(Davis et a1. 1990).
The world-wide trend towards a highly processed and refined diet which is not only
low in chromium but may also stimulate chromium losses may lead to marginal chromium
status. Mean intake for most developed countries is 50 to 60% of the lower end of the
estimated safe and adequate range (Anderson and Kozlovsky 1985). The Total Diet Study
found manganese intakes for teenage, adult, and elderly women to be slightly less than the
estimated safe and adequate daily dietary intake (Pennington et aI. 1989). Chromium and
manganese appear to have roles in the protection of pancreatic beta cells. H chromium/and
or manganese intakes are suboptimal, the beta cells may be increasingly susceptible to
oxidative stressors and/or to the effects of diabetogenic agents such as S12. The present
study was designed to study the effects of chromium and manganese adequacy and
deficiency on glucose metabolism in streptowtocin injected rats.
MATERIALS AND MElliODS
Animals and diets. Thirty-seven male weanling Sprague Dawley rats (Saseo, Inc.,
Omaha, NE) were housed in pairs in plastic cages with plastic gratings. Experimental diets
,
I
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and deionized water were available ad libitum. All animals were acclimatized. to the
conditions of the animal care facility before use. The rats were fed the semi-purified
American Institute of Nutrition (AIN-76) diet for mice and rats modified to be low in
chromium «400 ug/kg) for the first three weeks. (Table n.
Using a two by two factorial design the animals. were randomly assigned to casein-
based diets low in chromium and manganese (-Cr -Mn) or supplemented with 1 ppm
chromium as chromium chloride (+Cr) and 3 (-Mn) or 55 ppm (+Mn) manganese as
manganese carbonate (Cochran and Cox 1957).
StreptoZQtocin injectiQns. After seven weeks on the experimental diets, the rats
were injected on two consecutive days with 45 mg/kg body weight STZ in citrate buffer~
pH 4. One week fQllowing the STZ injections a glucose tQlerance test was perfonned
using a Ig1kg body weight glucose load. Approximately 0.5 ml Qf blood was conected
from the tail at 0, 60, 120, and 180 minutes. The blood samples were centrifuged and
serum samples stQred in ice fQr subsequent enzymatic analysis of glucose. (Procedure
#510, Sigma Chemical Co., St. Louis, MO)
NecrQPsy. Four weeks after STZ injections the animals were fasted for 12 hQurs in
metabolic cages, given a 19lkg body weight glucQse load, and two hours later anesthetized
with ketamine HCI (30 mg/kg) and xylazine (2.2 mg/kg) and exsanguinated. Blood
samples were collected from the tail priQr to the glucose load and by cardiac puncture at
necropsy. AU blood samples were centrifuged and serum was frozen for subsequent
analysis (glucose,. corticosterone, fructosamine, and insulin). Tissues were removed,
trimmed, weighed and frozen for subsequent mineral analysis. Analytical methods.
Glucose was determined enzymatical.ly using serum samples (Procedure #510, Sigma
Chemical Co., St Louis. MO). Insulin and corticosterone were detennined by
radioimmunoassay (Diagnostic Products Corp., Los Angel.es, CA). Fructosamine was
detennined using the ROTAG method (Roche Diagnostic Systems. Inc., Nutley, NI).
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For dietary chromium and manganese analyses, samples of the diets (200-250 mg)
were weighed into acid-washed borosilicate glass tubes and dried for 24 h at 100 degrees
C. Samples were then ashed in a muffle fumaee with no exposed metal heating elements
(Lindberg, Watertown, WI) with a dry ashing temperature of 375 degrees C. Dry ashing
was alternated with wet ashing with hydrogen peroxide and concentrated nitric acid (Hill et
aI. 1986). After ashing, samples were diluted with a 0.5% nitric acid (double-distilled;
GFS Chemicals, Powell, OH) and analyzed at 357.9 nm on a Perkin Elmer 5100PC atomic
absorption spectrophotometer with a graphite furnace and Zeeman background correction
(perkin Ebner Corp., Norwalk, Cf). Glass knives were used to cut the tissues for mineral
analysis. Drying and ashing procedures for tissues were identical to diet those used for the
analysis.
Statistical analysis. Data were analyzed using the generalized linear model (GLM)
procedure in the Statistical Analysis System (SAS). Differences among means were
identified using the least significant difference test. Repeated measures analysis was used
for glucose tolerance curves and repeated fasting glucose values (SAS Institute Inc. 1985).
RESULTS AND DISCUSSION
There was a significant (p<0.02) interactive effect between chromium and
mangan.ese affecting hepatic manganese concentrations (Table 2). In animals fed low
chromium diets, adequate dietary manganese increased hepatic manganese concentrations.
In animals fed diets adequate in chromium, dietary manganese did not affect hepatic
manganese concentrations. Bond et aI. reported significantly elevated hepatic manganese
concentrations in STZ-injected rats as compared to controls (1983).
There tended to be an interactive effect (p<O.lO) of chromium and manganese on
renal. manganese concentration. Mean renal manganese concentrations of rats fed: low
chromium diets were 2.31 6 0.25 ug/g and 3.44 6 0.41 uglg in rats fed low and adequate
manganese, respectively. Mean renal manganese concentrations of rats fed diets adequate
in chromium were 2.43 00.19 ug/g and 2.60 00.24 uglg in rats fed low and adequate
manganese, respectively. Mean renal manganese concentration ofrats fed the low
chromium and ,adequate manganese was significantly greater than that of rats fed all other
diets.
Although not significant (p<O.07), adequate clietar.y chromium tended to have an
effect on hepatic chromium concentrations. In rats fed either low or adequate manganese
diets, mean hepatic chromium concentrations were greater in rats fed diets adequate in
chromium than in rats fed low chromium diets. There no observed dietary effects of either
mineral on renal chromium concentration.
Failla and Gardell reported significantly elevated liver and kidney manganese
conoentrations in spontaneously diabetic BB Wistar rats as compared to their non-diabetic
controls (l985). Raz and Havivi studied the long tenn effects of STZ-induced diabetes and
found that renal and hepatic chromium concentrations of S1'2-injected rats did not
significantly differ from their age matched controls 180 days after injection (1988).
Seaborn and Stoecker found no effect of dietary chromium on hepatic chromium
concentration in lean and obese mice (1989).
Based on the data from this study, varying dietary trace mineral concentrations
affects tissue concentrations of selected minerals in S1'2-injected rats. It is possible that a
chronic diabetic state, as is seen with S1'2-injected rats, influences trace mineral
concentrations differently in some organs, possibly depleting excessive amounts of a
mineral from one organ and allowing accumulation in another.
The mean change in weight, from time of S1'2 injection to time of autopsy, varied
from a weight loss of 23 +-16 g in the rats fed low manganese and adequate chromium diet
to a weight gain of 6 +-20 g in rats fed diet low in chromium and manganese (Table 3).
There were no independent or interactive effects of dietary manganese or chromium on
change in body weight (p<O.20) ..
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TheIle was an significant (p<O.01') interactiv:e effect of dietary chromium.. and
manganese aIR spleen weight, expressed. as ~rcent body weight (fable 3). Rats fed a diet
adequate in chromium and manganese had a greater mean spleen weight as percent body
weight than did rats fed aU other diets.
Seminal vesicle weights, expressed as percent body weight, of animals fed diets
adequate in chromium tended to be greater than that of animals fed diets low in chromium
(p<o.06) (Table 3). Anderson and Polansky reported decreased spenn counts and
impaired fertility in male rats raised on a chromium deficient diet (1981). There were no
independent or interactive effects of dietary manganese or chromium seen in the following
tissues, expressed as percent body weight: kidney, pancreas, epididymal fat pad, or liver
(Table 3).
When applying repeated measures analysis of changes in fasting serum glucose
concentrations, from the day before STZ injection to four weeks after STZ injection (Figure
1), there was a significant (p<O.04) interactive effect of dietary chromium and manganese.
Rats fed a diet adequate in chromium and manganese had a smaller change in mean fasting
serum glucose concentration than did rats fed all other diets. The change in mean fasting
serum glucose concentrations varied from -0.7 mmol/L in the rats fed the +Cr +Mn diet to
+5.7 mmoVL in rats fed the diet Jow in chromium and adequate in manganese.
When repeated measures analysis is applied to the glucose tolerance CUlVes (Figure
2), the glucose tolerance curve of animals fed the diet adequate in chromium and
manganese tended to be lower than glucose tolerance curves of animals fed all other diets
(p<O.12). There was no significant effect of dietary chromium or manganese on mean
serum glucose concentrations at fasting or any of the individual one hour intervals
following the administration of the glucose load (Appendix A).
At autopsy the mean serum glucose concentrations of all treatment groups were
elevated (Table 4). This may be a combined effect of the stress of anesthesia and the
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glucose load. There was no significant difference in mean autopsy serum glucose
concentrations 120 minutes after a glucose load. (p<O.17).
There tended to be an interactive effect (p<O.08) of dietary chromium and
manganese on serum fructosamine concentrations at autopsy. Rats fed diets adequate in
chromium and manganese had lower mean serum fructosamine concentrations than did
animals fed all other diets. In a study of glycation of blood proteins in pregnant and
lactating rats, fructosamine followed a similar pattern of glucose control (Preston et aI.
1992). Because fructosamine is a measurement of intermediate (one to three weeks)
glucose control, the data from this study provide support for the improved glucose
tolerance seen in rats fed diets adequate in chromium and manganese as compared to other
experimental groups. Fructosamine appears to be a reliable indicator of glucose status as it
is not as affected by stress or dietary imake as is serum or blood glucose Preston 1986).
Although no significant differences in mean serum insulin concentrations were
observed (p<O.20), animals fed the diet low in chromium and manganese had a greater
mean serum insulin concentration that did animals fed all other diets. These data do not
show any significant effect of manganese on serum insulin concentration. However, HaIy
et aI. reported decreased circulating insulin in second generation manganese-deficient rats
as compared to their controls. First generation manganese deficient rats did not have
significantly different glucose tolerance from their controls (1984). It may be necessary to
induce the manganese deficiency in utero to have an effect on insulin synthesis.
There was a significant interactive effect of dietary manganese and chromium on
serum corticosterone concentrations (p<O.OO8). Rats fed the diet adequate in chromium and
manganese had lower mean serum corticosterone levels than did rats fed all other diets.
Conicosterone is the primary stress honnone in the rat. In a study of the effects of
immobilization stress on plasma corticosterone concentrations in rats, plasma corticosterone
concentrations of stressed rats were significantly greater than that of their controls
(Srivastava et a1. 1993). In a study of the effects of S1Z-induced chronic diabetes in rats,
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serum corticosterone concentrations were elevated in the SlZ-injected rats as compared to
their controls (Shires et aL 19&1). This provided further support for S17. acting as am
oxidative stressor. The data from this study indicate a decrease in stress in the rats fed the
diet adequate in chromium and manganese. If STZ is an oxidative stressor, the lower
serum glucose and fructosamine concentrations may possibly be explained by dietary
chromium and manganese having in interactive protective effect against the diabetogenic
action of STZ.
In conclusion, feeding S17.-injected rats diets adequate in chromium and
manganese appeared to have some protective effect on the diabetogenic actions of
streptozotocin. Compared to the other treatemem groups, they exhibited enhanced glucose
tolerance, less weight loss, and less stress as measured by serum corticosterone
concentrations. Rats fed diets adequate in chromium and manganese also had lower
fructosamine concentrations which indicated lower serum glucose for the one to three
weeks prior to autopsy.
TABLE 2
Group means ofmineral concentrations ofkidney and liver in SIZ-injected rats fed
diets low and adequate in chromium and manganese1,2
Kidney
Manganese
(uglg)
Liver Kidney
Chromium
(nglg)
Liver
-er -Mn 2.31 ± 0.25 3.74 ±0.62 31.3 ± 5.3 17.09 ± 5.6
-Cr+Mn 3.44 ± 0.41 7.57 ± 0.45 25.9 ± 5.1 32.9:1:: 12.8
+Cr-Mn 2.43 ± 0.19 5.36 ± 0.10 31.6 ± 8.2 43.8 ± 14.3
+Cr+Mn 2.60± 0.24 5.56 ± 0.40 34.6 ±6.5 51.8:1:: 13.7
Source ofvariation
Cr 0.22 0.78 0.50 0.07
Mn 0.03 0.008 0.86 0.33
CrxMn 0.10 0.016 0.52 0.75
1 Means±SEM
2 N; 8-10 w
-
TABLE 3
Group means ofchange in weight, from time ofinjection to autopsy, and tissue weights,
expressed as percent body weight, in SIZ-injected rats fed diets/ow and adequate in chromium and manganese 1,2
Change in weight
grams
Spleen
%
Seminal Vesicle
%
Kidney
%
Pancreas
%
Epididymal
fat pad
%
Liver
%
-Cr -Mn +6:1; 20 0.18 ± 0.01 0.22 ±0.02 0.92 ± 0.07 0.20;.1; 0.02 0.86±0.13 3.30 ± 0.14
-Cr +Mn -21 ± 20 0.18 ± 0.01 0.21 ± 0.02 1.02 ± 0.06 0.22 ±0.02 0.64±0.13 3.31 ± 0.12
+Cr -Mn -23 ± 16 0.17 ± 0.02 0.25 ±0.02 0.99 ± 0.05 0.23 ± 0.01 0.70 ± 0.14 3.32 ± 0.13
+Cr+Mn -4 ± 14 0.25 ±0.01 0.26 ± 0.03 0.93 ±0.06 0.22 ±0.O2 0.84 ± 0.05 3.31:f: 0.19
Source ofvariation
Cr 0.73 0.04 0.06 0.88 0.40 0.86 0.95
Mn 0.82 0.005 0.95 0.71 0.77 0.75 1.00
CrxMn 0.20 0.004 0.61 0.15 0.33 0.15 0.94
IMean± SEM
2N = 9-10
w
N
TABLE 4
Group means oJautopsy blood and serum parameters oJS1Z~;njectedratsJed
diets low and adequate in chromium and manganese 1,2
Glucose, fasting
(mmollL)
Glucose, necropsy3
(mmoIJL)
Fructosamine
(mmoUL)
Insulin
(pmoUL)
CorticQsterone
(nmoUL)
-Cr -Mn 10.39 ± 2.43 21.34 ± 1.66 1.89 ± 0.12 9.13 ± 1.69 109.2 ± 12.9
-Cr+Mn 11.82 ± 2.57 23.33 ± 1.42 1.94 ± 0.09 6.22 ± 0.66 274.4 ± 79.7
+Cr -Mn 10.68 ± 2.65 21.89 ± 1.58 1.99 ± O. II 6.66 ± 1.46 210.6 ± 55.8
+Cr+Mn 5.35 ± 1.00 18.71 ± 2.48 1.69 ± 0.05 6.96± 0.75 89.8 ± 16.6
Source ofvariation
Cr 0.18 0.27 0.42 0,49 0.41
Mn 0.40 0.75 0.21 0.30 0.66
CrxMn 0.15 0.17 0.07 0.20 0.008
I Mean±SEM
2 N::: 9-10
3120 minutes after I glkg body weight glucose load
I.H
I.H
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Figure 1: Fasting serum glucose concentrations before and in response to
STZ injections
35
22.5
20.0
17.5
-~
-'0 15.0
E
E
-CD
fI)
0 12.5<J
:::I
-C)
7.5
-Qo--Cr-Mn
+-Cr+Mn
-fr+Cr-Mn
++Cr+Mn
240180120
Time (Minutes)
so
s.O+---------r---------,------,...------..,
o
Figure 2: Mean serum glucose concentrations at fasting and at one hour
intervals during a glucose tolerance test (lglkg body wt) in STZ-
injected rats fed diets low or adequate in chromium and
manganese
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CHAPTER IV
SUMMARY, CONCLUSIONS, AND RECOMMENDAnONS
Summary
Thirty seven male weanling rats were randomly assigned to one of four
experimental diets varying only in amount of chromium and manganese. After seven
weeks on the experimental diets, animals were injected with S12 on two consectutive days
(45 mg/kg body weight, in citrate buffer, pH 4). One week after STZ injections, a glucose
tolerance test was performed. Four weeks after STZ injections, animals were fasted for 12
hours, and given a glucose load (1 g/kg body weight). Blood samples were collected
before and two hours after the glucose load. The animals were then killed and selected
tissues were collected for subsequently analyzed for paramters reflecting carbohydrate
metabolism.
Two hypotheses were listed in the introduction of this thesis. The first hypothesis
stated that there would be no statistically significant independent and/or interactive effect(s)
of dietary chromium and/or manganese on change in body weight, tissue weights as
percent body weight, glucose tolerance, or serum insulin, fructosamine, or corticosterone
concentrations in streptozotocin-injected rats. Dietary chromium and manganese
significantly decreased corticosterone concentrations, increased spleen weights as percent
body weight, and decreased SlZ-induced changes in fasting glucose. Therefore, we reject
the first null hypothesis.
The second hypothesis stated there would be no statistically significant independent
and/or interactive effects(s) ofdietary chromium and/or manganese of liver and kidney
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mineral concentrations in streptozotocin-injected rats. Adequate dietary manganese did
increase renal manganese concentrations and did increase hepatic manganese concentrations
when rats were fed a low chromium diet. Thus we reject the second null hypothesis.
Conclusions
Adequate dietary chromium and manganese increased spleen weight, as percent body
weight (p<O.OO5), tended to decrease serum fructosamine concentrations, (P<O.08), and
decreased corticosterone concentrations (p<O.008). Rats fed diets adequate in chromium
and manganese had smaner STZ-induced changes in fasting glucose (p<O.04).
Recommendations
To better assess the nature of the cytotoxic effects of S12, further research may include
an examination of pancreatic physiology and measurements of pancreatic SOD activity and
thiobarbituric acid-reacting products as indicators of lipid peroxidation and oxidative stress.
To investigate the effects of manganese deficiency it may be necessary to use a second
generation manganese-deficient rat or feed a diet with no added manganese. It would be
worthwhile to evaluate the effects of higher levels of supplemental chromium and
manganese on glucose metabolism in SlZ-injected rats.
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APPENDIX A
Group means ofserum glucose values atfasting and one hour Intervals during glucose tolerance tests
in STZ-injec/ed ra/sfed diets low and adequate in chromium and manganese1,2
o minutes 60 tninutcs
Glucose
(mmoUL)
120 minutes 180 minutes
-Cr-Mn 7.62 % 0.81 17.49 %1.99 13.82:t: 2.0S 11.S0:t: 2.01
-Cr+Mn 10.34:t: 1.78 21.16%2.07 17.31:t:2.S1 14.91 :t: 2.62
+Cr-Mn 8.32:t: 1.34 20.91 :t: 1.46 lS.60 :t: 2.22 13.SS %2.70
+Cr+Mn 6.49 :t: 0.50 18.24 % 1.97 14.44:t: 1.82 10.5S ;i; 1.38
Source ofvariation
Cr 0.21 0.88 0.80 0.61
Mn 0.72 0.80 0.59 0.93
CrxMn 0.07 0.10 0.29 0.11
I Meaos % SEM
2N=9-10
~
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